Abstract
In this cohort study we compared IgG antibody levels between infants immunized with 7-valent CRM197-conjugated pneumococcal vaccine (PCV-7) at 2,4 and 11 months and at 2, 3, 4 and 11 months of age,as measured by double adsorption ELISA. Pre- and post-booster levels following the 2 + 1 - and 3 + 1-dose schedule were comparable for 5 out of 7 serotypes except for serotypes 6B and 19F. The proportion of children reaching post-booster antibody thresholds were comparable except for 6B (>= 1.0 mu g/ml and >= 5.0 mu g/ml) and 19F (>= 5.0 mu g/ml). Surveillance studies are warranted for vaccine impact on 6B and 19F disease cases after reduced-dose PCV-7 schedules. (C) 2009 Elsevier Ltd. All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 1391-1396 |
Number of pages | 6 |
Journal | Vaccine |
Volume | 28 |
Issue number | 5 |
DOIs | |
Publication status | Published - 3-Feb-2010 |
Keywords
- Pneumococcal conjugate vaccine
- Immunogenicity
- Reduced-dose schedules
- STREPTOCOCCUS-PNEUMONIAE
- NASOPHARYNGEAL CARRIAGE
- LONGITUDINAL HOUSEHOLD
- OTITIS-MEDIA
- IMMUNOGENICITY
- CHILDREN
- DISEASE
- SAFETY
- IMMUNIZATION
- PROTECTION